These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23030324)

  • 1. What is next in sepsis: current trials in sepsis.
    Artigas A; Niederman MS; Torres A; Carlet J
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):859-62. PubMed ID: 23030324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conflicting clinical trial data: a lesson from albumin.
    Martin G
    Crit Care; 2005; 9(6):649-50. PubMed ID: 16356259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis.
    Eisen DP; Reid D; McBryde ES
    Crit Care Med; 2012 Jun; 40(6):1761-7. PubMed ID: 22610182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ crosstalk in critically ill patients: hemofiltration and immunomodulation in sepsis.
    Schefold JC; Hasper D; Jörres A
    Blood Purif; 2009; 28(2):116-23. PubMed ID: 19506367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sepsis in the critically-ill patient].
    Christensen VB; Nielsen JS; Tønnesen EK
    Ugeskr Laeger; 2007 Feb; 169(8):703-5. PubMed ID: 17313921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing mortality in severe sepsis and septic shock.
    Levinson AT; Casserly BP; Levy MM
    Semin Respir Crit Care Med; 2011 Apr; 32(2):195-205. PubMed ID: 21506056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China.
    Cheng B; Xie G; Yao S; Wu X; Guo Q; Gu M; Fang Q; Xu Q; Wang D; Jin Y; Yuan S; Wang J; Du Z; Sun Y; Fang X
    Crit Care Med; 2007 Nov; 35(11):2538-46. PubMed ID: 17828034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and coagulation: implications for the septic patient.
    Dellinger RP
    Clin Infect Dis; 2003 May; 36(10):1259-65. PubMed ID: 12746771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G-CSF and IL-8 for early diagnosis of sepsis in neonates and critically ill children - safety and cost effectiveness of a new laboratory prediction model: study protocol of a randomized controlled trial [ISRCTN91123847].
    Horisberger T; Harbarth S; Nadal D; Baenziger O; Fischer JE
    Crit Care; 2004 Dec; 8(6):R443-50. PubMed ID: 15566590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
    Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
    Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality.
    Zahar JR; Timsit JF; Garrouste-Orgeas M; Français A; Vesin A; Descorps-Declere A; Dubois Y; Souweine B; Haouache H; Goldgran-Toledano D; Allaouchiche B; Azoulay E; Adrie C
    Crit Care Med; 2011 Aug; 39(8):1886-95. PubMed ID: 21516036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice and perception--a nationwide survey of therapy habits in sepsis.
    Brunkhorst FM; Engel C; Ragaller M; Welte T; Rossaint R; Gerlach H; Mayer K; John S; Stuber F; Weiler N; Oppert M; Moerer O; Bogatsch H; Reinhart K; Loeffler M; Hartog C;
    Crit Care Med; 2008 Oct; 36(10):2719-25. PubMed ID: 18766100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathophysiology of sepsis and possible influence of statins].
    Fraunberger P; Drexel H; Walli AK
    Dtsch Med Wochenschr; 2010 Oct; 135(43):2128-32. PubMed ID: 20960384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial.
    Boerma EC; Koopmans M; Konijn A; Kaiferova K; Bakker AJ; van Roon EN; Buter H; Bruins N; Egbers PH; Gerritsen RT; Koetsier PM; Kingma WP; Kuiper MA; Ince C
    Crit Care Med; 2010 Jan; 38(1):93-100. PubMed ID: 19730258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects and mechanisms of insulin on systemic inflammatory response and immune cells in severe trauma, burn injury, and sepsis.
    Deng HP; Chai JK
    Int Immunopharmacol; 2009 Oct; 9(11):1251-9. PubMed ID: 19647101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surviving sepsis campaign: a critical reappraisal.
    Salluh JI; Bozza PT; Bozza FA
    Shock; 2008 Oct; 30 Suppl 1():70-2. PubMed ID: 18704005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the understanding of clinical manifestations and therapy of severe sepsis: an update for critical care nurses.
    Ely EW; Kleinpell RM; Goyette RE
    Am J Crit Care; 2003 Mar; 12(2):120-33; quiz 134-5. PubMed ID: 12625170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifle classification for predicting in-hospital mortality in critically ill sepsis patients.
    Chen YC; Jenq CC; Tian YC; Chang MY; Lin CY; Chang CC; Lin HC; Fang JT; Yang CW; Lin SM
    Shock; 2009 Feb; 31(2):139-45. PubMed ID: 18520698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure.
    Eisele B; Lamy M
    Semin Thromb Hemost; 1998; 24(1):71-80. PubMed ID: 9515782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.